Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/32758
Full metadata record
DC FieldValueLanguage
dc.contributor.authorThomas, T.-
dc.contributor.authorCasado, E.-
dc.contributor.authorGEUSENS, Piet-
dc.contributor.authorLems, W. F.-
dc.contributor.authorTimoshanko, J.-
dc.contributor.authorTaylor, D.-
dc.contributor.authorHofbauer, L. C.-
dc.date.accessioned2020-12-01T13:30:17Z-
dc.date.available2020-12-01T13:30:17Z-
dc.date.issued2020-
dc.date.submitted2020-11-05T13:17:23Z-
dc.identifier.citationOsteoporosis international, 31 (12) , p. 2303 -2311-
dc.identifier.urihttp://hdl.handle.net/1942/32758-
dc.description.abstractA panel of European experts was convened to establish consensus on a treat-to-target strategy in osteoporosis. Panellists agreed that the ultimate goals of treating osteoporosis are recovering pre-fracture functional level and reducing subsequent fracture risk; there was consensus that total hip bone mineral density is currently the most appropriate treatment target in clinical practice. Introduction A modified Delphi approach was convened to establish consensus among European experts on best practice management for patients with fragility fractures and whether a treat-to-target (T2T) strategy is applicable in osteoporosis. Methods A panel of 12 clinical experts (from eight European countries) voted on 13 final statements relating to a T2T strategy for osteoporosis across three rounds of blinded, remotely conducted electronic surveys (Likert scale: 'strongly disagree', 'disagree', 'unable to answer', 'agree', 'strongly agree'). When panellists disagreed, they were asked how the statement could be adjusted to allow for a positive response, which was used to refine the statement for the following round. Consensus was defined as >= 75% agreement with a statement. Panellists were selected by UCB Pharma, which provided financial and logistical support. Results Consensus was reached for 13/13 statements. Panellists agreed that the most important goals for fragility fracture patients are recovery of pre-fracture functional level and reduction of subsequent fracture risk. There was also consensus that a T2T strategy is applicable to osteoporosis and that bone mineral density (BMD) is currently the most clinically appropriate target. With regard to the definition of a specific BMD treatment target and timeframes applicable to T2T in osteoporosis, no clear consensus was reached; panellists emphasised that these would need to be individually determined. Conclusions According to a panel of European experts, the main goals of fracture management are to recover pre-fracture functional level and reduce fracture risk. Total hip BMD seems to be the most clinically appropriate treatment target within a T2T strategy.-
dc.description.sponsorshipThis study was sponsored by UCB Pharma and Amgen Inc. Support for study conception and design, acquisition of data, and analysis and interpretation of data, provided by Ogilvy Health, was funded by UCB Pharma and Amgen Inc. Support for third-party writing assistance for this article, provided by Kristian Clausen, MPH, Madeleine Warner, PhD, and Simon Foulcer, PhD, Costello Medical, UK was funded by UCB Pharma and Amgen Inc. in accordance with Good Publication Practice (GPP3) guidelines (http://www.ismpp.org/gpp3).-
dc.language.isoen-
dc.publisherSPRINGER LONDON LTD-
dc.rightsThe Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.-
dc.subject.otherBone mineral density-
dc.subject.otherDelphi panel-
dc.subject.otherFragility fracture-
dc.subject.otherOsteoporosis-
dc.subject.otherTreat-to-target-
dc.titleIs a treat-to-target strategy in osteoporosis applicable in clinical practice? Consensus among a panel of European experts-
dc.typeJournal Contribution-
dc.identifier.epage2311-
dc.identifier.issue12-
dc.identifier.spage2303-
dc.identifier.volume31-
local.format.pages9-
local.bibliographicCitation.jcatA1-
dc.description.notesTimoshanko, J (corresponding author), UCB Pharma, Slough, Berks, England.-
dc.description.notesjen.timoshanko@ucb.com-
dc.description.otherTimoshanko, J (corresponding author), UCB Pharma, Slough, Berks, England. jen.timoshanko@ucb.com-
local.publisher.place236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND-
local.type.refereedRefereed-
local.type.specifiedArticle-
dc.identifier.doi10.1007/s00198-020-05569-9-
dc.identifier.isiWOS:000557134200002-
dc.identifier.eissn-
dc.identifier.eissn1433-2965-
local.provider.typewosris-
local.uhasselt.uhpubyes-
local.description.affiliation[Thomas, T.] Univ Lyon, INSERM U1059, CHU St Etienne, St Etienne, France.-
local.description.affiliation[Casado, E.] Univ Hosp Parc Tauli, Sabadell, Spain.-
local.description.affiliation[Geusens, P.] Maastricht Univ, Maastricht, Netherlands.-
local.description.affiliation[Geusens, P.] Hasselt Univ, Hasselt, Belgium.-
local.description.affiliation[Lems, W. F.] Univ Amsterdam, Locat VUmc, Med Ctr, Amsterdam, Netherlands.-
local.description.affiliation[Timoshanko, J.] UCB Pharma, Slough, Berks, England.-
local.description.affiliation[Taylor, D.] Ogilvy Hlth, London, England.-
local.description.affiliation[Hofbauer, L. C.] Tech Univ Dresden, Ctr Hlth Aging, Dresden, Germany.-
local.description.affiliation[Hofbauer, L. C.] Tech Univ Dresden, Dept Med 3, Dresden, Germany.-
local.uhasselt.internationalyes-
item.validationecoom 2021-
item.contributorThomas, T.-
item.contributorCasado, E.-
item.contributorGEUSENS, Piet-
item.contributorLems, W. F.-
item.contributorTimoshanko, J.-
item.contributorTaylor, D.-
item.contributorHofbauer, L. C.-
item.accessRightsOpen Access-
item.fullcitationThomas, T.; Casado, E.; GEUSENS, Piet; Lems, W. F.; Timoshanko, J.; Taylor, D. & Hofbauer, L. C. (2020) Is a treat-to-target strategy in osteoporosis applicable in clinical practice? Consensus among a panel of European experts. In: Osteoporosis international, 31 (12) , p. 2303 -2311.-
item.fulltextWith Fulltext-
crisitem.journal.issn0937-941X-
crisitem.journal.eissn1433-2965-
Appears in Collections:Research publications
Files in This Item:
File Description SizeFormat 
Thomas2020_Article_IsATreat-to-targetStrategyInOs.pdfPublished version1.81 MBAdobe PDFView/Open
Show simple item record

WEB OF SCIENCETM
Citations

16
checked on Apr 30, 2024

Page view(s)

26
checked on Sep 6, 2022

Download(s)

10
checked on Sep 6, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.